Core Viewpoint - Bristol Myers (BMY) has faced a challenging first half of 2025, with shares down 16.3% year to date, underperforming both the industry and the S&P 500, primarily due to pipeline setbacks and generic competition despite some positive regulatory updates [1][3]. Financial Performance - The first-quarter performance exceeded expectations, leading to an increase in annual revenue guidance; however, the stock has declined since then, reflecting broader market concerns and skepticism about growth prospects [4]. - The Zacks Consensus Estimate for 2025 EPS has decreased from $6.87 to $6.76 over the past 60 days, while the estimate for 2026 has also dipped from $6.07 to $6.04 [18]. Generic Competition - BMY's legacy portfolio is negatively impacted by generic competition affecting key drugs such as Revlimid, Pomalyst, Sprycel, and Abraxane, along with the redesign of U.S. Medicare Part D [5]. - Sales of Eliquis, a major revenue contributor, fell by 4% in the first quarter due to the Medicare Part D redesign, although sales are expected to rise in the second half of 2025 as the coverage gap is eliminated [6]. New Drug Developments - BMY is focusing on newer drugs like Opdualag, Reblozyl, and Breyanzi to stabilize revenue as legacy drugs face competition; Reblozyl has shown strong growth since its approval [7]. - The immuno-oncology drug Opdivo has also seen solid revenue growth driven by volume increases, and recent approvals for new formulations and treatment regimens are expected to enhance its market position [9][10]. Pipeline Setbacks - Recent pipeline setbacks have negatively impacted BMY's stock, including disappointing results from the late-stage ODYSSEY-HCM study for Camzyos and the ARISE study for Cobenfy, which did not meet primary endpoints [13][14]. Debt and Valuation - BMY's strategy of acquiring companies has led to a high debt ratio, with long-term debt at $46.1 billion against cash and equivalents of $12.1 billion as of March 31, 2025 [15]. - The company's shares currently trade at a price/earnings ratio of 7.24x forward earnings, below its historical mean and the large-cap pharma industry's average [16]. Investment Outlook - Despite challenges, BMY's newer drugs and collaborations are expected to stabilize revenue and diversify its portfolio; however, the impact of generic competition remains a significant concern [20]. - The attractive dividend yield of 5.35% is a compelling reason for existing investors to maintain their positions in the stock [20].

This week's episode of the Express LIVE from @NYSE - @calebsilver is joined by @SamRo, why we're seeing a #buyback bonanza, and a look at what's ahead for markets this week.Investopedia (@Investopedia):Fear and Loathing on the Way to New Record Highs https://t.co/L600vHLpen ...

PRESS RELEASE Amsterdam, June 30, 2025 JDE Peet's (EURONEXT: JDEP), the world's leading pure-play coffee and tea company, today announced that it has repurchased 15,429 shares in the period from June 23, 2025 up to and including June 27, 2025. The shares were repurchased at an average price of EUR 24.10 per share for a total consideration of EUR 0.4 million. These repurchases were made as part of the EUR 250 million share buyback programme announced on March 3, 2025. jde-peets-SBB-periodic-update-june-30-20 ...

Target Circle Week runs July 6-12 and includes three unique "Deal of the Day" offerings all week on top of big discounts daily across the assortmentMembers of Target's paid program, Target Circle 360, get exclusive early access to the best deals of the week starting July 5 along with free same-day deliveryTeachers and students get 50% off a Target Circle 360 one-year membership to help make prepping for the school year easy and affordableMINNEAPOLIS, June 30, 2025 /PRNewswire/ -- Target Corporation (NYSE: T ...

Group 1 - Sydbank A/S announced a share buyback programme amounting to DKK 1,350 million, which commenced on 3 March 2025 and is set to conclude by 31 January 2026 [1][2] - The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S, executed in compliance with EU regulations [2] - During week 26, Sydbank A/S repurchased a total of 56,000 shares, with a gross value of DKK 24,565,660 [2] - The total number of shares repurchased under the programme to date is 1,149,000, with a gross value of DKK 487,371,500 [2][4] Group 2 - As of the latest transactions, Sydbank A/S holds a total of 1,149,222 own shares, representing 2.24% of the bank's share capital [4][5]

Company announcement no. 31 2025Danske BankBernstorffsgade 40DK-1577 København VTel. + 45 33 44 00 0030 June 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 26On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regul ...

Summary of Share Buyback Programme - The share buyback programme is set to run from June 2, 2025, to January 30, 2026, with a total buyback amount of up to DKK 1,000 million, limited to a maximum of 1,600,000 shares [1][2] - As of the latest report, a total of 518,400 shares have been repurchased, representing 2.04% of the bank's share capital [2] Transaction Details - The average purchase price for shares bought back under the programme is DKK 1,351.29, with a total expenditure of DKK 140,804,255 for 104,200 shares purchased during the reporting period [2] - Cumulatively, from January 28, 2025, to May 28, 2025, 414,200 shares were bought back at an average price of DKK 1,207.12, totaling DKK 499,988,706 [2] - The total number of shares repurchased under the programme since inception is 518,400 at an average price of DKK 1,236.10, amounting to DKK 640,792,961 [2] Compliance and Regulations - The programme is conducted in accordance with EU Commission Regulation No. 596/2014 and EU Commission Delegated Regulation No. 2016/1052, which provide a "Safe Harbour" for share buybacks [2] CEO Statement - The announcement is signed by John Fisker, CEO of Ringkjøbing Landbobank, indicating the bank's commitment to returning value to shareholders through the buyback programme [3]

But also there's this thing called chargebacks. Merchants like stable coins. They merchants like stable coins.The lower transaction cost because it's, you know, it's nothing. It's not 3%, 1%, 0 point. It's really super low.And this is why this is why Visa is tracking it. They're tracking all these transaction because they don't want to become obsolete. But they say tra chargebacks are also a problem.You know, people go on there like I want this and that. Ah, I don't want that. And then they have to charge a ...

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS St Peter Port, Guernsey 30 June 2025 NB Private Equity Partners (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 12 June 2025 and the share buy-back agreement with Jefferies International Limited. Transaction on Lo ...

6月30日，国内期市油脂油料板块大面积飘绿，菜籽粕主力涨逾1%。截至目前，菜籽粕主力上涨 1.14%，报2572.00元/吨；菜籽油主力下跌0.43%，报9421.00元/吨；棕榈油主力下跌0.69%，报8308.00 元/吨；豆油主力下跌0.32%，报7976.00元/吨。 6月30日油脂油料期货价格行情 | 合约名称 | 开盘价 | 昨收价 | 昨结价 | | --- | --- | --- | --- | | 豆油 | 7994.00 | 8002.00 | 8002.00 | | 棕榈油 | 8366.00 | 8376.00 | 8366.00 | | 菜籽油 | 9466.00 | 9466.00 | 9462.00 | | 豆粕 | 2942.00 | 2946.00 | 2938.00 | | 菜籽粕 | 2558.00 | 2559.00 | 2543.00 | | 豆一 | 4141.00 | 4140.00 | 4144.00 | | 豆二 | 3601.00 | 3603.00 | 3601.00 | | 花生 | 8178.00 | 8170.00 | 8170.00 | | 油菜籽 ...